216 related articles for article (PubMed ID: 34993745)
1. Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.
Wang TKM; Klein AL
Curr Cardiol Rep; 2022 Jan; 24(1):23-30. PubMed ID: 34993745
[TBL] [Abstract][Full Text] [Related]
2. Paradigm Shift in Diagnosis and Targeted Therapy in Recurrent Pericarditis.
Dong T; Klein AL; Wang TKM
Curr Cardiol Rep; 2023 Sep; 25(9):993-1000. PubMed ID: 37458866
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept for the treatment of recurrent pericarditis.
Fava AM; Reyaldeen R; Lo Presti S; Goyal A; Akintoye E; Hughes D; Klein AL
Expert Opin Biol Ther; 2022 Jan; 22(1):7-16. PubMed ID: 34757872
[TBL] [Abstract][Full Text] [Related]
5. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
[TBL] [Abstract][Full Text] [Related]
6. The Role of Rilonacept in Recurrent Pericarditis.
Presti SL; Elajami TK; Reyaldeen R; Anthony C; Klein AL
Heart Int; 2021; 15(1):20-25. PubMed ID: 36277322
[TBL] [Abstract][Full Text] [Related]
7. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.
Gupta M; Kaul S; Velazquez GR; Bandyopadhyay D; Fonarow GC; Klein A; Ghosh RK
Am J Cardiovasc Drugs; 2022 Jan; 22(1):27-33. PubMed ID: 34008144
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
Lin D; Klein A; Cella D; Beutler A; Fang F; Magestro M; Cremer P; LeWinter MM; Luis SA; Abbate A; Ertel A; Litcher-Kelly L; Klooster B; Paolini JF
BMC Cardiovasc Disord; 2021 Apr; 21(1):201. PubMed ID: 33882846
[TBL] [Abstract][Full Text] [Related]
9. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives.
Thomas GK; Bonaventura A; Vecchié A; van Tassell B; Imazio M; Klein A; Luis SA; Abbate A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):503-510. PubMed ID: 37163222
[TBL] [Abstract][Full Text] [Related]
11. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Imazio M; Klein AL; Brucato A; Abbate A; Arad M; Cremer PC; Insalaco A; LeWinter MM; Lewis BS; Lin D; Luis SA; Nicholls SJ; Sutej P; Wasserstrum Y; Clair J; Agarwal I; Wang S; Paolini JF;
J Am Heart Assoc; 2024 Mar; 13(6):e032516. PubMed ID: 38471825
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.
Brucato A; Lim-Watson MZ; Klein A; Imazio M; Cella D; Cremer P; LeWinter MM; Luis SA; Lin D; Lotan D; Pancrazi M; Trotta L; Klooster B; Litcher-Kelly L; Zou L; Magestro M; Wheeler A; Paolini JF;
J Am Heart Assoc; 2022 Oct; 11(20):e023252. PubMed ID: 36250662
[TBL] [Abstract][Full Text] [Related]
13. Rilonacept (Arcalyst) for recurrent pericarditis.
Med Lett Drugs Ther; 2021 Sep; 63(1632):143-144. PubMed ID: 34550114
[No Abstract] [Full Text] [Related]
14. Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis.
Affas ZR; Rasool BQ; Sebastian SA; Affas RS; Mohamadtahr SK; Saoor NH; Mohammad AN; Saoor GH; Husain BA; Touza R; Touza G; Amen S; Nazzaro W
Cureus; 2022 Nov; 14(11):e31226. PubMed ID: 36505131
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022.
Hagerty T; Kluge MA; LeWinter MM
Curr Cardiol Rep; 2022 Aug; 24(8):915-923. PubMed ID: 35612721
[TBL] [Abstract][Full Text] [Related]
16. Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.
Lo Presti S; Elajami TK; Reyaldeen R; Anthony C; Imazio M; Klein AL
J Am Heart Assoc; 2021 Oct; 10(19):e021685. PubMed ID: 34569270
[TBL] [Abstract][Full Text] [Related]
17. What is rilonacept's role in treating recurrent pericarditis?
Schwier NC
JAAPA; 2022 Nov; 35(11):18-19. PubMed ID: 36282574
[TBL] [Abstract][Full Text] [Related]
18. Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Feldman JM; Frishman WH; Aronow WS
Cardiol Rev; 2024 May; ():. PubMed ID: 38709249
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.
Klein AL; Lin D; Cremer PC; Nasir S; Luis SA; Abbate A; Ertel A; LeWinter M; Beutler A; Fang F; Paolini JF
Heart; 2020 Nov; 107(6):488-96. PubMed ID: 33229362
[TBL] [Abstract][Full Text] [Related]
20. Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Goel A; Bandyopadhyay D; Malik AH; Gupta R; Frishman WH; Aronow WS
Cardiol Rev; 2023 Jul-Aug 01; 31(4):225-229. PubMed ID: 36398320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
